By submitting this form you agree to be contacted by KirkendallDwyer.com affiliates and/or attorneys regarding your claim. You consent to KirkendallDwyer.com contacting you through the use of text message, phone call, and electronic mail message even if your number is a wireless number or if I am presently listed on a Do Not Call list. My consent does not require purchase.
Is Pradaxa, the first alternative to the original blood thinner warfarin, worth its $3000 a year price tag, or is it just as risky as the $200 a year warfarin? The number of Pradaxa injuries leading to lawsuits would indicate that the new drug isn’t a step forward for patients at all. The FDA approved…..
Is the FDA’s push to approve drugs more quickly costing too much in the way of patient safety? According to an article published in the Journal of the American Medical Association by two drug-safety experts, the answer is yes. They cite three drugs, including the controversial blood thinner Pradaxa, that were approved in an accelerated…..
After Pradaxa gained the infamous distinction of being the most deadly drug of 2011, the FDA vowed to investigate its safety further. On November 2, the FDA released a Drug Safety Communication explaining that the bleeding rates associated with Pradaxa use are not any higher than with warfarin use. Pradaxa is the first alternative to…..
Xarelto, an alternative to warfarin, the traditional treatment for atrial fibrillation, has suffered another rejection by the FDA. This is the second time that Johnson & Johnson has tried to get Xarelto approved to treat acute coronary syndrome, and the second time the FDA has refused to do so.